<DOC>
<DOCNO>EP-0624161</DOCNO> 
<TEXT>
<INVENTION-TITLE>
2'-DESOXY-ISOGUANOSINES, ISOSTER ANALOGUES AND ISOGUANOSINE DERIVATES AND THEIR USE
</INVENTION-TITLE>
<CLASSIFICATIONS>C07H1923	C07H1916	C07H2104	A61K317042	A61K3170	A61K317076	C07H1900	C07H19052	C07H1904	A61K317052	A61K317056	A61P3112	C07H2100	C12P1900	A61P3100	C07H2102	A61K317042	C07H2100	A61K3170	C12P1934	C07H1920	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07H	C07H	C07H	A61K	A61K	A61K	C07H	C07H	C07H	A61K	A61K	A61P	C07H	C12P	A61P	C07H	A61K	C07H	A61K	C12P	C07H	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07H19	C07H19	C07H21	A61K31	A61K31	A61K31	C07H19	C07H19	C07H19	A61K31	A61K31	A61P31	C07H21	C12P19	A61P31	C07H21	A61K31	C07H21	A61K31	C12P19	C07H19	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
BOEHRINGER MANNHEIM GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
ROCHE DIAGNOSTICS GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
KASIMIERCZUK ZIGMUNT
</INVENTOR-NAME>
<INVENTOR-NAME>
MUEHLEGGER KLAUS
</INVENTOR-NAME>
<INVENTOR-NAME>
SEELA FRANK
</INVENTOR-NAME>
<INVENTOR-NAME>
VON DER ELTZ HERBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
KASIMIERCZUK, ZIGMUNT
</INVENTOR-NAME>
<INVENTOR-NAME>
MUEHLEGGER, KLAUS
</INVENTOR-NAME>
<INVENTOR-NAME>
SEELA, FRANK
</INVENTOR-NAME>
<INVENTOR-NAME>
VON DER ELTZ, HERBERT
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Oligonucleotides which contain one or several of
the heterocyclic bases mentioned in compounds of

the general formulae II - IV


in which

R
3
 =
hydrogen or a protecing group,
W and Z
can independently of one another denote =
hydrogen, halogen, NH-(CH
2
)
n
NH
2
 (n = 2-12),
R-CH
2
COOH (R = alkylene-C 1-8), a reporter or
intercalator group

and 


in which

R3 =
hydrogen or a protecting group,
Z
denotes hydrogen, halogen, NH-(CH
2
)
n
NH
2

(n = 2-12), R-CH
2
COOH (R = alkylene-C 1-8),
a reporter or intercalator group

and are capable of forming parallel nucleic acid
complexes.
Oligonucleotides as claimed in claim 1 which can
form complementary double strands with a second

oligonucleotide containing an isocytidine.
Oligonucleotides as claimed in claims 1 and 2,
whose internucleotide bond contains

methylphosphonate and/or phosphothioate groups.
Oligonucleotide as claimed in claims 1 to 3,
wherein it is composed of 6 to 100 nucleotide

building blocks. 
Compounds of the general formula II and IV


in which

R
1
 =
hydrogen or a protecting group, PO
3
H
2
, P
2
O
6
H
3
,
P
3
O
9
H
4
 or the corresponding alpha, beta and
gamma thiophosphates
R
2
 =
hydroxy, phosphoramidite, methylphosphonate,
H-phosphonate, a reporter or intercalator

group provided that R
2
 is not OH if R
1
, R
3
, W
and Z each represent hydrogen
R
3
 =
hydrogen or a protecting group
W and Z
can independently of one another denote
hydrogen, halogen, NH-(CH
2
)
n
NH
2
 (n = 2-12),
R-CH
2
COOH (R = alkylene-C 1-8),

a reporter group or intercalator group. 
Compounds of the general formula III,


in which

R
1
 =
is a protecting group,
R
2
 =
phosphoramidite, H-phosphonate, methylphosphonate,
a reporter or intercalator group
R
3
 =
hydrogen or a protecting group
W and Z
can independently of one another denote
hydrogen, halogen, NH-(CH
2
)
n
NH
2
 (n = 2-12),
R-CH
2
COOH (R = alkylene-C 1-8),

a reporter group or intercalator group.
Compounds as claimed in claims 5 and 6 in which the
heterocyclic bases carry protecting groups.
Process for the production of oligonucleotides as
claimed in claims 1 - 4, wherein the condensation

is carried out with compounds as claimed in claims
5 - 7. 
Process as claimed in claim 8, wherein in the
compounds of the general formulae II - IV R
1

represents a triphosphate or alpha, beta or gamma
thiophosphate analogues of these phosphoric acid

esters and R
2
 represents a reporter group or an
intercalator group and the condensation is carried

out enzymatically by polymerases by the "nick
translation" and "random priming" methods.
Process as claimed in claim 8, wherein in the
compounds of the general formulae II - IV R
2

represents a phosphoramidite, a H-phosphonate or a
methylphosphonate group, R
1
 represents a protecting
group and the condensation is carried out by

chemical synthesis.
Use of compounds as claimed in claims 10 to 13 for
the production of pharmaceutical preparations with

antiviral activity.
</CLAIMS>
</TEXT>
</DOC>
